Stem definition | Drug id | CAS RN |
---|---|---|
1712 | 5588-33-0 |
Dose | Unit | Route |
---|---|---|
0.20 | g | O |
0.20 | g | P |
Property | Value | Reference |
---|---|---|
MRTD (Maximum Recommended Therapeutic Daily Dose) | 10.81 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Date | Agency | Company | Orphan |
---|---|---|---|
Feb. 27, 1970 | FDA |
None
None
None
None
Source | Code | Description |
---|---|---|
ATC | N05AC03 | NERVOUS SYSTEM PSYCHOLEPTICS ANTIPSYCHOTICS Phenothiazines with piperidine structure |
FDA CS | M0016525 | Phenothiazines |
MeSH PA | D014150 | Antipsychotic Agents |
MeSH PA | D002491 | Central Nervous System Agents |
MeSH PA | D002492 | Central Nervous System Depressants |
MeSH PA | D015259 | Dopamine Agents |
MeSH PA | D018492 | Dopamine Antagonists |
MeSH PA | D018377 | Neurotransmitter Agents |
MeSH PA | D011619 | Psychotropic Drugs |
MeSH PA | D014149 | Tranquilizing Agents |
CHEBI has role | CHEBI:48561 | dopaminergic antagonists |
CHEBI has role | CHEBI:65190 | typical antipsychotic drugs |
FDA EPC | N0000175746 | Phenothiazine |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Schizophrenia | indication | 58214004 | DOID:5419 |
Hyperkalemia | contraindication | 14140009 | |
Neuroleptic malignant syndrome | contraindication | 15244003 | DOID:14464 |
Orthostatic hypotension | contraindication | 28651003 | |
Hypokalemia | contraindication | 43339004 | |
Conduction disorder of the heart | contraindication | 44808001 | |
Epilepsy | contraindication | 84757009 | DOID:1826 |
Stupor | contraindication | 89458003 | |
Tardive dyskinesia | contraindication | 102449007 | |
Prolonged QT interval | contraindication | 111975006 | |
Coma | contraindication | 371632003 | |
Granulocytopenic disorder | contraindication | 417672002 | |
Congenital long QT syndrome | contraindication | 442917000 | |
Predisposed to Torsades de Pointes Cardiac Arrhythmias | contraindication |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 9.22 | Basic |
pKa2 | 3.45 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
5-hydroxytryptamine receptor 2A | GPCR | ANTAGONIST | Ki | 8.13 | PDSP | CHEMBL | |||
D(2) dopamine receptor | GPCR | ANTAGONIST | Ki | 7.72 | PDSP | CHEMBL | |||
Muscarinic acetylcholine receptor M1 | GPCR | Ki | 8 | PDSP | |||||
D(1A) dopamine receptor | GPCR | ANTAGONIST | Ki | 6.99 | IUPHAR | ||||
Potassium voltage-gated channel subfamily H member 2 | Ion channel | IC50 | 6.50 | CHEMBL | |||||
5-hydroxytryptamine receptor 1A | GPCR | ANTAGONIST | Ki | 6.98 | IUPHAR | ||||
5-hydroxytryptamine receptor 2C | GPCR | Ki | 6.80 | PDSP | |||||
5-hydroxytryptamine receptor 6 | GPCR | Ki | 6.42 | PDSP | |||||
Muscarinic acetylcholine receptor M2 | GPCR | Ki | 7.82 | PDSP | |||||
Muscarinic acetylcholine receptor M3 | GPCR | Ki | 7.05 | PDSP | |||||
Muscarinic acetylcholine receptor M4 | GPCR | Ki | 7.72 | PDSP | |||||
Muscarinic acetylcholine receptor M5 | GPCR | Ki | 7.22 | PDSP | |||||
D(3) dopamine receptor | GPCR | Ki | 8.59 | PDSP | |||||
D(4) dopamine receptor | GPCR | Ki | 8.04 | PDSP | |||||
Histamine H1 receptor | GPCR | Ki | 8.74 | PDSP |
ID | Source |
---|---|
4019816 | VUID |
N0000147905 | NUI |
D00795 | KEGG_DRUG |
32672-69-8 | SECONDARY_CAS_RN |
4019063 | VANDF |
4019816 | VANDF |
C0025497 | UMLSCUI |
CHEBI:6780 | CHEBI |
CHEMBL1088 | ChEMBL_ID |
CHEMBL1201052 | ChEMBL_ID |
DB00933 | DRUGBANK_ID |
D008653 | MESH_DESCRIPTOR_UI |
C529599 | MESH_SUPPLEMENTAL_RECORD_UI |
4078 | PUBCHEM_CID |
7227 | IUPHAR_LIGAND_ID |
2019 | INN_ID |
5XE4NWM740 | UNII |
203186 | RXNORM |
5058 | MMSL |
d00889 | MMSL |
001490 | NDDF |
004594 | NDDF |
372852001 | SNOMEDCT_US |
75268009 | SNOMEDCT_US |
78684000 | SNOMEDCT_US |
None